Former CNET editor Dong Ngo has been involved with technology since 2000, starting with testing gadgets and writing code for CNET Labs' benchmarks. He managed CNET's San Francisco Labs, reviews 3D ...

Click to share on X (Opens in new window) X Click to share on Facebook (Opens in new window) Facebook Almost a quarter century ago today, the Xbox debuted one of its most distinct launch titles — and ...

Arcellx leverages proprietary platforms like D-Domain, ddCAR, and ARC-SparX to enhance immune response, targeting multiple myeloma, AML, MDS, and solid tumors. ACLX's lead therapy, anito-cel, shows ...

Cel-Sci is struggling to commercialize its Multikine cancer therapy; it recently closed on a small but expensive financing. The company has completed its initial end of phase 3 meeting with the FDA; ...

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's ...

Crypto lending platform Celsius Network has an approximately $1.2 billion gap in its balance sheet, with most liabilities owed to its users. In addition, the firm has filed for bankruptcy protection, ...

This new Registration Study targets the population of previously untreated resectable stage 3 and 4 head and neck cancer patients who had no lymph node involvement and low PD-L1 tumor expression.

Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis by means of ex vivo clustered regularly interspaced short palindromic repeats ...

The CEL Core program enhances the talents and abilities of practicing entrepreneurs. The mentor-driven program empowers entrepreneurs to overcome business challenges, create new opportunities and ...

Abeona Therapeutics Inc. announced progress in its Biologics License Application (BLA) review for prademagene zamikeracel (pz-cel), a potential treatment for recessive dystrophic epidermolysis bullosa ...